Xenon Pharmaceuticals Reports Q1 2025 Revenue Surge to $7.5M; Net Loss Widens to $65M

Reuters

2025/05/13

Xenon Pharmaceuticals Reports Q1 2025 Revenue Surge to $7.5M; Net Loss Widens to $65M

Xenon Pharmaceuticals Inc. reported financial results for the first quarter ended March 31, 2025. The company recognized revenue of $7.5 million for this period, compared to no revenue in the same period in 2024, primarily due to a milestone payment from the Neurocrine collaboration. The net loss for the quarter increased to $65.0 million from $47.9 million in the previous year, driven by higher research and development expenses related to the azetukalner program and increased personnel-related costs. General and administrative expenses rose to $19.0 million from $14.8 million in the first quarter of 2024, attributed to an increase in employee headcount. Research and development expenses were $61.2 million, up from $44.3 million, due to ongoing clinical trials and pre-clinical programs. Xenon continues to advance its pipeline, with patient recruitment for the Phase 3 azetukalner X-TOLE2 study expected to complete in the coming months and topline results anticipated in early 2026. Additionally, the company plans to initiate Phase 3 studies for azetukalner in MDD and BPD mid-year and expects to start a Phase 1 study for XEN1701 in Q3 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xenon Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9449534-en) on May 12, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2535895467"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2535895467\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2535895467?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-13 04:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2535895467","market":"nz","top_or_hot":-1,"title":"Xenon Pharmaceuticals Reports Q1 2025 Revenue Surge to $7.5M; Net Loss Widens to $65M","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Xenon Pharmaceuticals Reports Q1 2025 Revenue Surge to $7.5M; Net Loss Widens to $65M\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Xenon Pharmaceuticals Inc. reported financial results for the first quarter ended March 31, 2025. The company recognized revenue of $7.5 million for this period, compared to no revenue in the same period in 2024, primarily due to a milestone payment from the Neurocrine collaboration. The net loss for the quarter increased to $65.0 million from $47.9 million in the previous year, driven by higher research and development expenses related to the azetukalner program and increased personnel-related costs. General and administrative expenses rose to $19.0 million from $14.8 million in the first quarter of 2024, attributed to an increase in employee headcount. Research and development expenses were $61.2 million, up from $44.3 million, due to ongoing clinical trials and pre-clinical programs. Xenon continues to advance its pipeline, with patient recruitment for the Phase 3 azetukalner X-TOLE2 study expected to complete in the coming months and topline results anticipated in early 2026. Additionally, the company plans to initiate Phase 3 studies for azetukalner in MDD and BPD mid-year and expects to start a Phase 1 study for XEN1701 in Q3 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xenon Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9449534-en) on May 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Xenon Pharmaceuticals Reports Q1 2025 Revenue Surge to $7.5M; Net Loss Widens to $65M</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nXenon Pharmaceuticals Reports Q1 2025 Revenue Surge to $7.5M; Net Loss Widens to $65M\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-05-13 04:01</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Xenon Pharmaceuticals Reports Q1 2025 Revenue Surge to $7.5M; Net Loss Widens to $65M\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Xenon Pharmaceuticals Inc. reported financial results for the first quarter ended March 31, 2025. The company recognized revenue of $7.5 million for this period, compared to no revenue in the same period in 2024, primarily due to a milestone payment from the Neurocrine collaboration. The net loss for the quarter increased to $65.0 million from $47.9 million in the previous year, driven by higher research and development expenses related to the azetukalner program and increased personnel-related costs. General and administrative expenses rose to $19.0 million from $14.8 million in the first quarter of 2024, attributed to an increase in employee headcount. Research and development expenses were $61.2 million, up from $44.3 million, due to ongoing clinical trials and pre-clinical programs. Xenon continues to advance its pipeline, with patient recruitment for the Phase 3 azetukalner X-TOLE2 study expected to complete in the coming months and topline results anticipated in early 2026. Additionally, the company plans to initiate Phase 3 studies for azetukalner in MDD and BPD mid-year and expects to start a Phase 1 study for XEN1701 in Q3 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xenon Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9449534-en) on May 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"XENE","symbol_name":"Xenon製藥","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250512:nNDLc2GKmQ:1","article_id":"2535895467","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2535895467","pubTimestamp":1747080077,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Xenon Pharmaceuticals Inc. reported financial results for the first quarter ended March 31, 2025. The company recognized revenue of $7.5 million for this period, compared to no revenue in the same period in 2024, primarily due to a milestone payment from the Neurocrine collaboration. The net loss for the quarter increased to $65.0 million from $47.9 million in the previous year, driven by higher research and development expenses related to the azetukalner program and increased personnel-related costs. General and administrative expenses rose to $19.0 million from $14.8 million in the first quarter of 2024, attributed to an increase in employee headcount. Research and development expenses were $61.2 million, up from $44.3 million, due to ongoing clinical trials and pre-clinical programs. Xenon continues to advance its pipeline, with patient recruitment for the Phase 3 azetukalner X-TOLE2 study expected to complete in the coming months and topline results anticipated in early 2026. Addit","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"XENE":"Xenon制药","NDAQ":"纳斯达克OMX交易所"},"translate_title":"Xenon Pharmaceuticals报告2025年第一季度收入飙升至750万美元；净亏损扩大至6500万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"XENE":0.9},"content_text":"Xenon Pharmaceuticals Reports Q1 2025 Revenue Surge to $7.5M; Net Loss Widens to $65M\n    \n\n        Xenon Pharmaceuticals Inc. reported financial results for the first quarter ended March 31, 2025. The company recognized revenue of $7.5 million for this period, compared to no revenue in the same period in 2024, primarily due to a milestone payment from the Neurocrine collaboration. The net loss for the quarter increased to $65.0 million from $47.9 million in the previous year, driven by higher research and development expenses related to the azetukalner program and increased personnel-related costs. General and administrative expenses rose to $19.0 million from $14.8 million in the first quarter of 2024, attributed to an increase in employee headcount. Research and development expenses were $61.2 million, up from $44.3 million, due to ongoing clinical trials and pre-clinical programs. Xenon continues to advance its pipeline, with patient recruitment for the Phase 3 azetukalner X-TOLE2 study expected to complete in the coming months and topline results anticipated in early 2026. Additionally, the company plans to initiate Phase 3 studies for azetukalner in MDD and BPD mid-year and expects to start a Phase 1 study for XEN1701 in Q3 2025.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xenon Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9449534-en) on May 12, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}